VK2735: Keep the Route in the Result
AXON Research Institute • AXON Peptide affiliation
Educational draft • Scientific + legal review pending
Silent film with full on-screen captions. Conceptual illustrations, not molecular structures.

VK2735 activates GIP and GLP-1 receptors. Its research includes different formulations, making the route of administration an important part of every evidence claim. The phase two VENTURE study tested the injectable formulation against placebo in adults with obesity or overweight and a related condition, excluding diabetes. Over 13 weeks, the study reported greater body-weight reduction with VK2735. The most common adverse events were gastrointestinal. These are short-term trial findings. An oral formulation needs its own evidence on absorption, tolerability, and outcomes. Results from an injectable study cannot establish equivalent performance for a tablet or an unrelated research product.

END CARD
Research explained. Not medical advice. Sources and limitations in the accompanying transcript.

SOURCES
[1] VENTURE investigators (2026): Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management
https://pubmed.ncbi.nlm.nih.gov/41508550/
Primary human randomized phase 2 VENTURE trial

[2] Viking Therapeutics (2026): Initiation of VK2735 oral phase 3 clinical program
https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity
Official sponsor development update, not independent efficacy evidence

EVIDENCE LIMITATIONS
Thirteen weeks does not establish durable maintenance or rare long-term risks.
The phase 2 paper describes an injectable formulation, not oral efficacy.
Sponsor development updates identify study status, not proof of clinical benefit.

TOPIC INVENTORY PROVENANCE (not reused audiovisual media)
VK2735: Keep the Route in the Result